Real-World Outcomes Among Medicare Beneficiaries Treated With First-Line Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia
· daniel a. ermann, md
AI Briefing
- • Zanubrutinib showed longer real-world treatment duration and time to next treatment in older CLL patients.
- • Zanubrutinib was associated with better overall survival compared to acalabrutinib and ibrutinib.
- • Study analysis was based on Medicare Fee-for-Service data.
Source Summary
Daniel A. Ermann, MD, reviews a large Medicare Fee-for-Service analysis showing zanubrutinib was associated with longer real-world treatment duration, time to next treatment, and overall survival vs acalabrutinib and ibrutinib in older patients with first-line CLL.
Advertisement